Failure to lyse venous thrombi because of elevated plasminogen activator inhibitor 1 (PAI-1) and 4G polymorphism of its promotor genome (The PAI-1/4G syndrome)

Clinical and Applied Thrombosis/Hemostasis

Volumn 16, Issue 5, 2010, Pages 574-578

  Bern, Murray M ^a   McCarthy, Nancy ^a  

^a NEW ENGLAND BAPTIST HOSPITAL   (United States)

Author keywords

4G>5G genome; Deep vein thrombosis; Fibrinolysis; Plasminogen; Plasminogen activator inhibitor; Promoter genome; Thrombosis

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ALLELE; ARTICLE; BLOOD CLOT LYSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; FEMALE; GENETIC POLYMORPHISM; GENOME; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PROMOTER REGION; VEIN THROMBOSIS;

ALLELES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; VENOUS THROMBOSIS;

EID: 77955860782     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029610361334     Document Type: Article

References (59)

1. Fay, WP Thrombotic and hemorrhagic disorders due to abnormal fibrinolysis. UpToDate. 2009.
2. Fay WP, Shapiro AD, Shih JL, Schleef RR, Ginsburg D. Brief report: complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation. N Eng J Med. 1992 ; 327 (24). 1729-1733.
3. Fay WP, Parker AC, Condrey LR, Shapiro AD Human plasminogen activator inhibitor-1 (PAI-1) deficiency: characterization of a large kindred with a null mutation in the PAI-1 gene. Blood. 1997 ; 90 (1). 204-248.
4. Scheef RR, Higgins DL, Pillemer E., Levitt LJ Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor. J Clin Invest. 1989 ; 83: 1747-1752.
5. Lisman T., de Groot PG, Meijers JC, Rosendaal RF Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood. 2005 ; 105 (3). 1102-1105.
6. Burzotta F., Iacoviello L., Di Castelnuovo A., et al. 4G/5G PAI-1 promoter polymorphism and acute-phase levels of PAI-1 following coronary bypass surgery: a prospective study. J Thromb Thrombolysis. 2003 ; 16 (3). 149-154.
7. Chen YL, Zhang JX, Wang PX, et al. Association of 4G/5G polymorphism in PAI-1 promoter with PAI1 level in deep vein thrombosis. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2005 ; 22 (6). 624-627.
8. Tsantes AE, Nikolopoulos GK, Bagos PG, et al. Association between the plasminogen activator inhibitor-1 4G/5G polymorphism and venous thrombosis. A meta-analysis. Thromb Haemost. 2007 ; 97 (6). 907-913.
9. Grubic N., Stegnar M., Peternel P., Kaider A., Binder BR A novel G/A and the 4G/5G polymorphism within the promoter of the plasminogen activator inhibitor-1 gene in patients with deep vein thrombosis. Thromb Res. 15;84 (6). 431-443.
10. Stegnar M., Uhrin P., Peternel P., et al. The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thromboembolism. Thromb Haemost. 1998 ; 79 (5). 975-979.
11. Renkens R., Roelofs JJ, de Waard V., et al. The role of plasminogen activator inhibitor type 1 in the inflammatory response local tissue injury. J Thromb Haemost. 2005 ; 3 (5). 1018-1025.
12. Robinson SD, Dawson P., Ludlam CA, Boon NA, Newby DE Vascular and fibrinolytic effects of intra-arterial tumor necrosis factor alpha in patients with coronary heart disease. Clin Sci (Lond). 2006 ; 110 (3). 353-360.
13. Kruithof EK, Gudinchet A., Bachmann F. Plasminogen activator inhibitor 1 and plasminogen activator inhibitor 2 in various disease states. Thromb Haemost. 1988 ; 59 (1). 7-12.
14. Martínez-Calatrava MJ, Martínez-Larrad MT, Zabena C., González-Sánchez JL, Fernández-Pérez C., Serrano-Ríos M. The 4G/5G PAI-1 genotype is associated with elevated plasma PAI-1 levels regardless of the variables of the metabolic syndrome and smoking status. A population-based study in Spanish population. Diabetes Obes Metab. 2007 ; 9 (1). 134-135.
15. Sartori MT, Wiman B., Vettore S., Dazzi F., Girolami A., Patrassi GM 4G/5G polymorphism of PAI-1 gene promoter and fibrinolytic capacity in patients with deep vein thrombosis. Thromb Haemost. 1998 ; 80 (6). 956-960.
16. Quest Diagnostics Nichols Institute. 33608 Oretga Highway, San Juan Capistrano, CA 92690.
17. Folsom AR, Cushman M., Heckbert SR, Rosamond WD, Aleksic N. Prospective study of fibrinolytic markers and venous thromboembolism. J Clin Epidemiol. 2003 ; 56 (6). 598-603.
18. Gori AM, Marcucci R., Fatini C., et al. Impaired fibrinolysis in retinal vein occlusion: a role for genetic determinants of PAI-1 levels. Thromb Haemost. 2004 ; 92 (1). 54-60.
19. Ridker PM, Hennekens CH, Lindpaintner K., Stampfer MJ, Miletich JP Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men. Circulation. 1997 ; 95 (1). 59-62.
20. Mansilha A., Araújo F., Severo M., Sampaio SM, Toledo T., Albuquerque R. Genetic polymorphisms and risk of recurrent deep vein thrombosis in young people: prospective cohort study. Eur J Vasc Endovasc Surg. 2005 ; 30 (5). 545-549.
21. Crowther MA, Roberts J., Roberts R., et al. Fibrinolytic variables in patients with recurrent venous thrombosis: a prospective cohort study. Thromb Haemost. 2001 ; 85 (3). 390-394.
22. Segui R., Estelles A., Mira Y., et al. PAI-1 promoter 4G/5G genotype as an additional risk factor for venous thrombosis in subjects with genetic thrombophilic defects. Br J Haematol. 2000 ; 111 (1). 122-128.
23. Zoller B., Garcia de Frutos P., Dahlback B. A common 4G allele in the promoter of the plasminogen activator inhibitor (PAI-1) gene is a risk factor for pulmonary embolism and arterial thrombosis in hereditary protein S deficiency. Thromb Haemost. 1998 ; 79 (4). 802-807.
24. Tassies D., Espinosa G., Munoz-Rodriquez FJ, et al. The 4G/5G polymorphism of the type 1 plasminogen activator inhibitor gene and thrombosis in patients with antiphospholipid syndrome. Arthritis Rheum. 2000 ; 43 (10). 2349-2358.
25. Testa R., Bonfigi AR, Sirolla C., et al. C-reactive protein is directly related to plasminogen activator inhibitor type1 (PAI-1) levels in diabetic subjects with the 4G allele at position -675 of the PAI-1 gene. Nutr Meta Cardiovasc Dis. 2008 ; 18 (3). 220-226.
26. Yasuda S., Tsutsumi A., Atsumi T., et al. Gene polymorphisms of tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with antiphospholipid antibodies. J Rheumatol. 2002 ; 29 (6). 1192-1197.
27. Verschuur M., Jellema A., Bladbjerg EM, et al. The plasminogen activator inhibitor-1 (PAI-1) promoter haplotype is related to PAI-1 plasma concentrations in lean individuals. Atherosclerosis. 2005 ; 181 (2). 275-284.
28. Visanji JM, Seargent J., Tahri D., et al. Influence of the -675 4G/ 5G dimorphism of the plasminogen activator inhibitor 1 promoter on thrombotic risk in patients with factor V Leiden. Br J Haematol. 2000 ; 110 (1). 135-138.
29. Barcellona D., Fenu L., Cauli C., Pisu G., Marongui F. Allele 4G of the gene PAI-1 associated with prothrombin mutation G20210A increases the risk for venous thrombosis. Thromb Haemost. 2003 ; 90 (6). 1061-1064.
30. Balta G., Altay C., Gurgey A. PAI-1 gene 4G/5G genotype: a risk factor for thrombosis in vessels of internal organs. Am J Hematol. 2002 ; 71 (2). 89-93.
31. Oguzulgen K., Demirtas S., Erkekol FO, et al. The role of plasminogen activator inhibitor -1 polymorphism, factor-V-Leiden, and prothrombin-20210 mutations in pulmonary thromboembolism. Clin Appl Thromb Hemost. 2009 ; 15 (1). 73-77.
32. Harbourne T., O'Brien D., Nicolaides AN Fibrinolytic activity in patients with idiopathic and secondary deep vein thrombosis. Throm Res. 1991 ; 64 (5). 543-550.
33. Caprini JA, Arcelus JI, Hoffman KN, et al. Venous duplex imaging follow-up of acute symptomatic deep vein thrombosis of the leg. J Vasc Surg. 1995 ; 21 (3). 472-476.
34. Killewich LA, Macko RF, Cox K., et al. Regression of proximal deep venous thrombosis is associated with fibrinolytic enhancement. J Vasc Surg. 1997 ; 26 (5). 861-868.
35. Meissner MH, Zierier BK, Bergelin RO, Chandler WL, Strandness DE Jr. Coagulation, fibrinolysis, and recanalization after deep vein thrombosis. J Vasc Surg. 2002 ; 35 (2). 278-285.
36. Arcelus JI, Caprini JA, Hoffman KN, et al. Laboratory assays and duplex scanning outcomes after symptomatic deep vein thrombosis: preliminary results. J Vasc Sur. 1996 ; 23 (4). 616-621.
37. Nguyen G., Horellou MH, Kruithof EK, Conard J., Samama MM Residual plasminogen activator inhibitor activity after venous stasis as a criterion for hypofibrinolysis: a study in 83 patients with confirmed deep vein thrombosis. Blood. 1988 ; 72 (2). 601-605.
38. Podor TJ, Singh D., Clindemi P., et al. Vimentin exposed on activated platelets and platelet microparticles localizes vitronectin and plasminogen activator inhibitor complexes on their surface. J Biol Chem. 2002 ; 277 (9). 7529-7539.
39. Pósán E., Ujj G., Kiss A., Telek B., Rák K., Udvardy M. Reduced in vitro clot lysis and release of more active platelet PAI-1 in polycythemia vera and essential thrombocythemia. Thromb Res. 1998 ; 90 (2). 51-56.
40. Nicholls SC, Hoffer EK, Chandler WL Failure of peripheral arterial thrombolysis due to elevated plasminogen activator inhibitor type 1. Blood Coagul Fibrinolysis. 2003 ; 14 (8). 729-733.
41. Sartori MT, Danesin C., Saggiorato G., et al. The PAI-1 gene 4G/5G polymorphism and deep vein thrombosis in patients with inherited thrombophilia. Clin Appl Thromb Hemost. 2003 ; 9 (4). 299-307.
42. Falkowski A., Kaczmarczyk M., Goracy I., et al. Pharmacogenetics of the local thrombolysis in patients with deep vein thrombosis. Pol Arch Med Wewn. 2005 ; 114 (1). 644-651.
43. Arts J., Grimbergen J., Bosma PJ, Rahmsdorf HJ, Kooistra T. Role of c-Jun and proximal phorbol 12-myristate-13-acetate-(PMA)-responsive elements in the regulation of basal and PMAstimulated plasminogen-activator-inhibitor-1 gene in HepG2. Eur J Biochem. 1965 ; 241 (2). 393-402.
44. Lucore CL, Fujii S., Wun TC, Sobel BE, Billadello JJ Regulation of the expression of type 1 plasminogen activator inhibitor in Hep2c cells by epidermal growth factor. J Biol Chem. 1988 ; 263 (31). 15845-15848.
45. Hopkins WE, Westerhausen DR Jr, Sobel BE, Billadello JJ Transcriptional regulation of plasminogen activator inhibitor type-1 mRNA in Hep G2 cells by epidermal growth factor. Nucleic Acids Res. 1991 ; 19 (1). 163-168.
46. Nordt TK, Eschenfelder E., Peter K., Sobel BE, Bode C. Independence of growth factor induced plasminogen activator inhibitor type 1 (PAI-1) expression from the 4G/5G polymorphism of the PAI-1 gene. Thromb Haemost. 2003 ; 90 (1). 36-42.
47. Keeton MR, Curriden SA, van Zonneveld AJ, Loskutoff DJ Identification of regulatory sequences in the type 1 plasminogen activator inhibitor gene responsive to transforming growth factor beta. J Biol Chem. 1991 ; 266 (34). 23048-23052.
48. Ding Z., Pan JQ Distribution of PAI-1 promoter 4G/5G polymorphism in healthy Chinese and functional characterization using a luciferace reporter vector. Ann Hematol. 2005 ; 84 (3). 183-187.
49. McCormack LJ, Semple JI, Stickland MH, Barrett JH, Grant PJ The effect of number of Days in culture and plasminogen activator inhibitor-1 (PAI-1) 4G/5G genotype on PAI-1 antigen release by cultured human umbilical vein endothelial cells. Thromb Res. 1998 ; 92 (5). 199-206.
50. Chen YQ, Sloan-Lancaster J., Berg DT, Richardson MA, Grinnell B., Tseng-Crank J. Differential mechanisms of plasminogen activator inhibitor-1 gene activation by transforming growth factor-beta and tumor necrosis factor-alpha in endothelial cells. Thromb Haemost. 2002 ; 86 (6). 1563-1572.
51. Ma Z., Jhun B., Jung SY, Oh CK Binding of upstream stimulatory factor 1 to the E-box regulates the 4G/5G polymorphism-dependent plasminogen activator inhibitor 1 expression in mast cells. J Allergy Clin Immunol. 2008 ; 121 (4). 1006-1012.
52. Westerhausen DR Jr, Hopkins WE, Billadello JJ Multiple transforming growth factor-beta- inducible elements regulate expression of the plasminogen activator inhibitor type-1 gene in Hep G2 cells. J Biol Chem. 1991 ; 266 (2). 1092-1100.
53. van Zonneveld AJ, Curriden SA, Loskutoff DJ Type 1 plasminogen activator inhibitor gene: functional analysis and glucocorticoid regulation of its promoter. Proc Natl Acad Sci U S A. 1988 ; 85 (15). 5525-5529.
54. Brown NJ, Murphey LJ, Srikuma N., Koschachuhanan N., Williams GH, Vaughan DE Interactive effect of PAI-1 4G/5G genotype and salt intake on PAI-1 antigen. Arterioscler Thromb Vasc Biol. 2001 ; 21 (6). 1071-1077.
55. Hoekstra T., Geleijnse JM, Schouten EG, Kluft C. Diurnal variation in PAI-1 activity predominantly confined to the 4G-allele of the PAI-1 gene. Thromb Haemost. 2002 ; 88 (5). 794-798.
56. Schoenhard JA, Smith LH, Painter CA, Eren M., Johnson CH, Vaughan DE Regulation of the PAI-1 promoter by circadian clock components: differential activation by BMAL1 and BMAL2. J Mol Cell Cardiol. 2003 ; 35 (5). 473-481.
57. Levin EG, Santell L. Conversion of the active to latent plasminogen activator inhibitor from human endothelial cells. Blood. 1987 ; 70 (4). 1090-1098.
58. Santell L., Levin EG. Cyclic AMP potentiates phorbol ester stimulation of tissue plasminogen activator release and inhibits secretion of plasminogen activator inhibitor-1 from human endothelial cells. J Biol Chem. 1988 ; 263 (32). 16802-16808.
59. Konkle BA, Kollros PR, Kelly MD Heparin-binding growth factor-1 modulation of plasminogen activator inhibitor-1 expression. Interaction with cAMP and protein kinase c- mediated pathways. J Biol Chem. 1990 ; 265: 21867-21873.